Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
BMJ Open ; 3(1)2013 Jan 29.
Article in English | MEDLINE | ID: mdl-23364319

ABSTRACT

OBJECTIVES: To investigate the efficacy and safety of Vancomycin Ophthalmic Ointment 1% (Toa Pharmaceutical Co., Ltd, Toyama, Japan) in patients with external ocular infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). DESIGN: A case series. SETTING: This study was a multicentre, open-label, uncontrolled study in Japan approved as orphan drug status. PARTICIPANTS: Patients with MRSA or MRSE external ocular infections unresponsive to the treatment of fluoroquinolone eye drops. INTERVENTIONS: Vancomycin Ophthalmic Ointment 1% was administered four times daily. PRIMARY AND SECONDARY OUTCOME MEASURES: The subjective and objective clinical scores and bacterial cultures were collected at days 0 (baseline), 3, 7 and 14. The primary outcome was clinical response evaluation (efficacy rate) determined as complete response, partial response, no response and worsening. Secondary outcome was the eradication of the bacteria. Safety was assessed by adverse events including cases in which neither MRSA nor MRSE was detected. RESULTS: Twenty-five cases with MRSA (20) or MRSE (5) infections were enrolled. Of these 25 cases, 4 discontinued the treatment due to the negative results for bacterial culture during screening or at baseline. Of the 21 cases with conjunctivitis (14), blepharitis (3), meibomitis (1), dacryocystitis (2) or keratitis (1), 14 (66.7%) cases were evaluated as being excellently (complete response, 2 cases) or well (partial response, 12 cases) treated. The eradication rates were 68.4% in MRSA (13 of 19 cases) and 100% in MRSE (2 of 2 cases). Ten adverse events occurred in 7 (28.0%) of 25 cases at the local administration site. CONCLUSIONS: Vancomycin Ophthalmic Ointment 1% was considered to be useful for the treatment of intractable ocular MRSA/MRSE infections.

2.
Food Chem ; 138(4): 2210-8, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23497878

ABSTRACT

This study investigated the influence of Goishi-tea on visceral fat weight in induced obese mice. Mice were divided into two main groups, normal and obesity. In obesity group, mice were fed with high-fat diet. Goishi-tea including its fractions (ethyl-acetate layer and water layer) was administrated in normal and obesity three sub-groups. Results showed no influence of Goishi-tea in normal group. However, visceral fat weight, size of adipose cell and cholesterol level were significantly decreased in obesity group fed Goishi-tea compared to control group. Moreover, adiponectin levels tended to increase and adipocytokines has significant values lower in obesity group fed Goishi-tea compared to control group. Interestingly, Goishi tea involved in the high-fat diet induced-obese mice can inhibit fat accumulation and maintain adiponectins without increasing tumor necrosis factor-alpha and interleukin-6. It would be beneficial for the prevention of metabolic syndrome and obesity-related disorder.


Subject(s)
Adipokines/metabolism , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Camellia sinensis/chemistry , Plant Extracts/administration & dosage , Adipose Tissue/physiopathology , Animals , Body Weight/drug effects , Female , Humans , Intra-Abdominal Fat/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Mice, Obese , Obesity/metabolism , Phytotherapy , Tea/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL